Caliber Launches 4 Analytics and AI-driven Solutions to Revolutionize Pharma Manufacturing and Quality

March 12, 2025 06:00 PM PDT | By Cision
 Caliber Launches 4 Analytics and AI-driven Solutions to Revolutionize Pharma Manufacturing and Quality
Image source: Kalkine Media

PITTSBURGH, March 13, 2025 /PRNewswire/ -- Caliber recently launched 4 digital solutions that further strengthen its portfolio and also position the company at the forefront of the Pharma 4.0 revolution. These innovations integrate AI and next-gen technologies, reinforcing Caliber's commitment towards preparing the life sciences industry for the future with holistic digital enablement and enhanced compliance.

The Launch of Caliber’s groundbreaking solutions at Caliber Commune 2025
The Launch of Caliber’s groundbreaking solutions at Caliber Commune 2025

With over 23 years of global expertise, Caliber continues to transform pharmaceutical and biotechnology companies with GxP Quality solutions across Quality Control, Quality Assurance, Manufacturing, and Data and Insights. These solutions help companies stay compliant and competitive in today's complex regulatory environment.

"Throughout our 23 years, we have built future-driven products that add immense value to the industry, and even in the current evolving technological landscape, we continue to stay ahead with solutions that help companies to address the challenging regulatory, technology, and economic landscapes," said Sekhar Surabhi, CEO and Founder, Caliber, also the Chair of ISPE India's Pharma 4.0 Community of Practice (CoP).

The newly launched solutions, CalGenie, CaliberMetrix, CaliberPulse, and CalWare360 were introduced at Caliber's user forum event, Caliber Commune 2025. The event, which attracted over 400 industry leaders, highlighted how Data and AI can drive continuous improvement in quality performance.

CalGenie, a pharma-focused, Gen AI-powered tool designed to streamline a company's internal Quality Value Chain. Acting like a "genie," it delivers instant answers, performs complex calculations, and generates intelligent summaries with simple prompts, empowering users with real-time insights. Available as a mobile app, it works seamlessly offline for anytime, anywhere access.

CaliberMetrix, aligned with FDA's quality metrics guidance, offers a comprehensive, real-time view of quality performance, enabling companies to identify inefficiencies and mitigate compliance risks.

CaliberPulse, a pharma-focused statistical analysis tool, integrates with actual data sources leading to accurate predictions enhancing proactiveness, sustainability and cost-effectiveness.

CalWare360 is a warehouse management system which enhances security, traceability, and compliance through material lifecycle management, offering digitalized racking, real-time inventory tracking, and smart integration with ERP and EBR

Caliber's flagship product, CaliberLIMS, set a precedent as the first 100% paperless lab in India and created many such labs worldwide. The newly launched version, CaliberLIMS4.0, supports next-gen QC laboratories. With global presence in Pittsburgh, Netherlands, and India, serving over 16 countries, Caliber continues to empower the pharmaceutical industry with AI-powered solutions that help companies stay compliant in an evolving digital landscape.

For more information, visit www.caliberuniversal.com.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Sponsored Articles


Investing Ideas

Previous Next